



File

#15

FORM PTO-1449

Att. Docket No.: REG 142-C

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

USPN : 09/577,468

Applicant: Wong, et al.

Date Filed: May 24, 2000

Title: USE OF MODIFIED CILIARY
NEUROTROPHIC FACTOR

Examiner: R. Clinton

Group Art Unit: 1647

April 23, 2003

RECEIVED
MAY 06 2003
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Publication Number	Publication Date	Name
----------------------	------------------	---------------	-----------------------	---------------------	------

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes No
RCV	WO98/22128	5/28/1998	PCT		
	EP 1010432A1	6/21/2000	Europe		
	WO91/04316	4/4/1991	PCT		
↓	WO91/19009	12/12/1991	PCT		

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, etc.)

RCV
↓

Miller, R.G., et al, Annals of Neurology (1996) Vol.39, No. 2, pp. 256-260, XP008005507, "A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis."

Miller, R.G., et al, Neurology (1996), Vol. 47, No. 5, pp. 1329-1331, XP001064801, "Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis."

PMayer 9/23/03